Her main research concerns Receptor, Biochemistry, Stereochemistry, Internal medicine and Endocrinology. Her study in Receptor is interdisciplinary in nature, drawing from both Insulin receptor and Binding site. Her study on Peptide, Enzyme inhibitor, Binding protein and Enzyme is often connected to Steroid as part of broader study in Biochemistry.
Her biological study spans a wide range of topics, including Agonist, Antagonist, IC50, Tachykinin receptor 1 and Chemical synthesis. In the field of Internal medicine, her study on Thermogenin, Brown adipose tissue and Adipose tissue overlaps with subjects such as Gastric motility and Antrum. Her Motilin study in the realm of Endocrinology interacts with subjects such as Monoaminergic.
Receptor, Stereochemistry, Biochemistry, Internal medicine and Endocrinology are her primary areas of study. Her Receptor study combines topics from a wide range of disciplines, such as Binding site and Cell biology. Her Stereochemistry research includes themes of In vitro, Chemical synthesis, Antagonist, Substance P and Trifluoromethyl.
Her research in Biochemistry focuses on subjects like Molecular biology, which are connected to Enzyme-linked receptor. Particularly relevant to Neuropeptide Y receptor is her body of work in Internal medicine. Her Endocrinology research integrates issues from Neuropeptide and Partial agonist.
Margaret A. Cascieri focuses on Stereochemistry, Receptor, Chemical synthesis, Agonist and In vitro. Her Stereochemistry study incorporates themes from CCR2, Antagonist and Trifluoromethyl. Her research investigates the connection with Receptor and areas like Endocrinology which intersect with concerns in Partial agonist.
Margaret A. Cascieri interconnects Bicyclic molecule, Substituent, Structure–activity relationship and Piperidine in the investigation of issues within Chemical synthesis. Margaret A. Cascieri combines subjects such as Oral administration, Beta-3 adrenergic receptor, Adrenergic receptor and Lipolysis with her study of Agonist. Her research integrates issues of Urea and Triazole derivatives in her study of In vitro.
Margaret A. Cascieri mostly deals with Receptor, Agonist, Pharmacology, Internal medicine and Endocrinology. Her Receptor research entails a greater understanding of Biochemistry. Within one scientific family, Margaret A. Cascieri focuses on topics pertaining to Glucagon under Biochemistry, and may sometimes address concerns connected to Transmembrane domain and Glucagon-like peptide 1 receptor.
The various areas that Margaret A. Cascieri examines in her Agonist study include Chemical synthesis, Bioavailability, Lipolysis and Stereochemistry. Her research ties Antagonist and Stereochemistry together. Her biological study spans a wide range of topics, including Blockade, Gene and Peptide.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Distinct Mechanism for Antidepressant Activity by Blockade of Central Substance P Receptors
Mark S. Kramer;Neal Cutler;John Feighner;Ram Shrivastava.
Science (1998)
Azasteroids: structure-activity relationships for inhibition of 5.alpha.-reductase and of androgen receptor binding
Gary H. Rasmusson;Glenn F. Reynolds;Nathan G. Steinberg;Edward Walton.
Journal of Medicinal Chemistry (1986)
Receptor for motilin identified in the human gastrointestinal system.
Scott D. Feighner;Carina P. Tan;Karen Kulju McKee;Oksana C. Palyha.
Science (1999)
Peroxisome Proliferator-Activated Receptors γ and α Mediate in Vivo Regulation of Uncoupling Protein (UCP-1, UCP-2, UCP-3) Gene Expression
Linda J. Kelly;Pasquale P. Vicario;G. Marie Thompson;Mari R. Candelore.
Endocrinology (1998)
Nonpeptidal peptidomimetics with a β-D-glucose scaffolding. A partial somatostatin agonist bearing a close structural relationship to a potent, selective substance P antagonist
R. Hirschmann;K. C. Nicolaou;S. Pietranico;J. Salvino.
Journal of the American Chemical Society (1992)
Cloning and Expression of a Novel Neuropeptide Y Receptor
David H. Weinberg;Dalip J.S. Sirinathsinghji;Carina P. Tan;Lin-Lin Shiao.
Journal of Biological Chemistry (1996)
Molecular cloning and characterization of a new receptor for galanin
Andrew D Howard;Carina Tan;Lin-Lin Shiao;Oksana C Palyha.
FEBS Letters (1997)
Species Differences in Prostatic Steroid 5α-Reductases of Rat, Dog, and Human
Tehming Liang;Margaret A. Cascieri;Anne H. Cheung;Glenn F. Reynolds.
Endocrinology (1985)
Human β3-adrenergic receptor agonists containing 1,2,3-triazole-substituted benzenesulfonamides
Linda L Brockunier;Emma R Parmee;Hyun O Ok;Mari R Candelore.
Bioorganic & Medicinal Chemistry Letters (2000)
Structural Optimization Affording 2-(R)-(1-(R)-3,5-Bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a Potent, Orally Active, Long-Acting Morpholine Acetal Human NK-1 Receptor Antagonist
J. J. Hale;S. G. Mills;M. Maccoss;P. E. Finke.
Journal of Medicinal Chemistry (1998)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
MSD (United States)
Schering-Plough
MSD (United States)
MSD (United States)
MSD (United States)
Medicines for Malaria Venture
MSD (United States)
Harvard Medical School
MSD (United States)
Scripps Research Institute
Georgia Institute of Technology
University of California, Riverside
Facebook (United States)
Wayne State University
National Research Centre, Egypt
Wuyi University
University of Nottingham
University of Toronto
Nanjing University of Information Science and Technology
Wake Forest University
Johannes Gutenberg University of Mainz
University of Pittsburgh
The University of Texas at Arlington
Thomas Jefferson University
The University of Texas Southwestern Medical Center
University of Colorado Anschutz Medical Campus